Fulgent Genetics reported first‑quarter 2026 revenue of $71.1 million, a 3.2% decline from $73.5 million in the same period last year, and a GAAP net loss of $24.8 million versus a $11.5 million loss in Q1 2025. The company’s non‑GAAP earnings per share were $‑0.36, missing the consensus estimate of $‑0.11 and falling short of the GAAP EPS of $‑0.80.
The revenue drop was driven largely by a loss of a large customer that shifted testing in‑house, which reduced laboratory services revenue. Segment‑level data show Precision Diagnostics generated $40.2 million, Anatomic Pathology $25.1 million, and Biopharma Services $5.8 million. Biopharma Services grew 43.2% year‑over‑year, offsetting some of the decline in laboratory services.
Gross margins compressed in the quarter: GAAP gross margin fell to 30.2% from 32.5% a year earlier, while non‑GAAP gross margin slipped to 32.3% from 34.5%. The compression reflects lower testing volumes, a backlog of claims processing, and higher integration costs associated with the recent acquisitions of Bako Diagnostics and StrataDx.
Management maintained full‑year 2026 revenue guidance at $350 million but revised its non‑GAAP loss guidance to $‑1.59 per share from $‑1.45, citing the impact of share repurchases. The company expects gross margins to normalize and improve in the second half of the year as operational efficiencies take effect.
CEO Ming Hsieh said the transition of the largest customer was a significant headwind but emphasized the company’s focus on leveraging recent acquisitions and its AI‑driven digital pathology platform. CFO Paul Kim noted that lower volume and claims backlog were the primary drivers of the margin compression. The earnings miss on non‑GAAP EPS contributed to a negative market reaction, with investors focusing on the company’s ability to manage the customer transition and sustain margin improvement.
In the long term, Fulgent’s strong cash position of $604.7 million, ongoing share repurchases, and progress in its therapeutic pipeline (FID‑007 and FID‑022) provide upside potential. However, the short‑term headwind from the customer transition and margin compression will likely continue to weigh on quarterly performance until the company’s integration and volume recovery are fully realized.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.